Our Research

Enhanced Pet Sciences is pleased to announce the completion and publishing of the final phases of its CBD canine studies, a multi-year clinical trial demonstrating safety, dosing, the absence of immune response or contraindication to vaccines, and efficacy in the areas of anti-inflammation, anti-itching, insulin (diabetic) regulation, microbiome support, anti-fungal and anti-oxidative functions, all under agreement with the University of Kentucky’s Food and Animal Sciences Department. The final phases of these canine studies can be found for a limited time at the under-construction website: https://epscpets.com/our-research/

Dr. David Harmon of the University of Kentucky’s Food and Animal Sciences Department states “Beyond the safety aspects demonstrated in earlier trials, these latest studies demonstrate various beneficial increases and decreases in canine metabolic and sub-metabolic activity after 3 weeks of using Enhanced Pet Sciences’ CBD Pet Chews at dosing of 4.5mg of CBD per kg of body weight.”

EPS points to the following key takeaways from this latest publication:

• Several metabolites were identified as potential biomarkers for changes in the canine metabolome by CBD that point to the reduction of inflammation. 
• The up-regulation and down-regulation of several key metabolites were identified which point to pathways by which CBD can exert suspected anti-inflammatory, antioxidant, anti-obesity and anti-diabetic effects. 
• Such up-regulation and down-regulation of metabolites that point to potential for CBD to influence lipid, carbohydrate, amino acid, vitamin, and nucleotide metabolism in the body as well as benefits to the gut microbiome such as the promotion of beneficial bacteria and gut health.
• Decrease in biomarkers related to fungal infection. 
• Other plant phytonutrient metabolites with anti-inflammatory, anti-bacterial, and wound healing properties. 

Reid Parr, Director of Research at EPSC is pleased with the completion of this muti-year study stating: “The first phases of our canine studies validated safety, dosing, palatability and an indication of anti-itching function. The second phases validated the use of CBD without immune response or contraindication to vaccines. These final phases have validated not only the indication of anti-inflammatory functions that we suspected by way of the results we’ve seen on our equine studies, but also some of the different mechanisms in the body by which these various desired effects are taking place. I am very pleased to see that our unique formulation of CBD infused pet chews can produce these helpful results, that they have not shown to do any harm, and that we can now move forward with our regulatory indication applications with the aim of making them widely available across global mass-market retail networks.”

Michael French, President of EPSC added, “Pet Parents love their pets and must be their advocate, trust is key. We have seen a lot of mystery in the CBD space without any credible history, we chose a different path. With the completion of these trials, EPSC has taken a huge step towards earning the trust of pet parents.”